Nov 01, 2023 8:24am EDT iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific
Oct 10, 2023 8:00am EDT iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics
Aug 14, 2023 4:15pm EDT iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development
Jun 27, 2023 8:00am EDT iBio Appoints Dr. Martin Brenner as CEO, Felipe Duran as CFO to Oversee Company’s Next Stage of Growth
Jun 06, 2023 8:00am EDT iBio Expands Tech Stack with EngageTx™; Adds TROP-2 Bispecific to Development Pipeline
